The spin-off hits the headlines again as an innovative approach to fight autoimmune diseases.

 

Ahead Therapeutics SL is a spin-off company shared by the Germans Trias i Pujol Research Institute (IGTP), the Catalan Institute of Nanoscience and Nanotechnology (ICN2) and the Catalan Institution for Research and Advanced Studies (ICREA). It offers the opportunity to exploit a technology based on encapsulation in liposomes for a wide range of autoimmune diseases.

On Sunday August 26 La Vanguardia interviewed the researchers behind it, including ICREA Prof. Daniel Maspoch, Head of the ICN2 Supramolecular Nanochemistry and Materials Group.

Read the article at www.lavanguardia.com.

 

Supported by:

This site uses cookies and similar technologies.

If you not change browser settings, you agree to it. Learn more

I understand